Signal Genetics, which develops and sells cancer diagnostics, raised $9 million by offering 850,000 shares at $10, within the range of $10.00 to $12.00. Signal Genetics plans to list on the NASDAQ under the symbol SGNL. Signal Genetics initially filed confidentially on 11/12/2013. Aegis Capital Corp. acted as lead manager on the deal.
